Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: siRNA therapeutics - OliX Pharmaceuticals

Next Previous
Drug Profile

Research programme: siRNA therapeutics - OliX Pharmaceuticals

Alternative Names: asiRNA therapeutics - OliX Pharmaceuticals; BMT 101; cp-asiRNA therapeutics - OliX Pharmaceuticals; OLX 10020; OLX 103; OLX 201; OLX 301; OLX 401; OLX 701

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMolecular Therapeutics
  • Developer OliX Pharmaceuticals; University of Virginia School of Medicine
  • Class Analgesics; Antifibrotics; Antivirals; Eye disorder therapies; Skin disorder therapies; Small interfering RNA
  • Mechanism of Action Connective tissue growth factor inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain disorders
  • No development reported Age-related macular degeneration; Atopic dermatitis; COVID 2019 infections; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Neuropathic pain
  • Discontinued Cancer; Herpes simplex virus infections

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Neuropathic-pain in South Korea (Intrathecal, Injection)
  • 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in South Korea
  • 10 May 2022 Preclinical development in Neuropathic-pain is ongoing in South Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top